These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18161661)

  • 1. Standardization of PSA measures: a reappraisal and an experience with WHO calibration of Beckman Coulter Access Hybritech total and free PSA.
    Vignati G; Giovanelli L
    Int J Biol Markers; 2007; 22(4):295-301. PubMed ID: 18161661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.
    Stephan C; Kahrs AM; Klotzek S; Reiche J; Müller C; Lein M; Deger S; Miller K; Jung K
    Clin Chem Lab Med; 2008; 46(5):623-9. PubMed ID: 18839463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations.
    Garrido MM; Marta JC; Ribeiro RM; Pinheiro LC; Holdenrieder S; Guimarães JT
    In Vivo; 2021; 35(6):3431-3439. PubMed ID: 34697179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access prostate-specific antigen assays.
    Fillée C; Tombal B; Philippe M
    Clin Chem Lab Med; 2010 Feb; 48(2):285-8. PubMed ID: 20001849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers.
    Stephan C; Bangma C; Vignati G; Bartsch G; Lein M; Jung K; Philippe M; Semjonow A; Catalona WJ
    Int J Biol Markers; 2009; 24(2):65-9. PubMed ID: 19634108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.
    Stephan C; Klaas M; Müller C; Schnorr D; Loening SA; Jung K
    Clin Chem; 2006 Jan; 52(1):59-64. PubMed ID: 16391327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?
    Stephan C; Köpke T; Semjonow A; Lein M; Deger S; Schrader M; Miller K; Jung K
    Clin Chem Lab Med; 2009; 47(11):1325-31. PubMed ID: 19778292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardization of assay methods reduces variability of total PSA measurements: an Irish study.
    Forde JC; Marignol L; Blake O; McDermott T; Grainger R; Crowley VE; Lynch TH
    BJU Int; 2012 Sep; 110(5):644-50. PubMed ID: 22897326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
    de la Taille A; Houlgatte A; Houdelette P; Goluboff ET; Berlizot P; Ricordel I
    Br J Urol; 1998 Sep; 82(3):389-92. PubMed ID: 9772876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant prostate specific antigen test results despite WHO assay standardization.
    Boegemann M; Arsov C; Hadaschik B; Herkommer K; Imkamp F; Nofer JR; Gerß J; Albers P; Semjonow A
    Int J Biol Markers; 2018 Aug; 33(3):275-282. PubMed ID: 29734838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability of assay methods for total and free PSA after WHO standardization.
    Foj L; Filella X; Alcover J; Augé JM; Escudero JM; Molina R
    Tumour Biol; 2014 Mar; 35(3):1867-73. PubMed ID: 24092573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection.
    Jansen FH; Roobol M; Bangma CH; van Schaik RH
    Clin Chem; 2008 Dec; 54(12):1999-2006. PubMed ID: 18927249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.
    Slev PR; La'ulu SL; Roberts WL
    Am J Clin Pathol; 2008 Jun; 129(6):952-8. PubMed ID: 18480013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
    Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
    Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA.
    Patel D; White PA; Milford Ward A
    BJU Int; 2000 Apr; 85(6):686-9. PubMed ID: 10759666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation.
    Kort SA; Martens F; Vanpoucke H; van Duijnhoven HL; Blankenstein MA
    Clin Chem; 2006 Aug; 52(8):1568-74. PubMed ID: 16762996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
    Miller MC; O'Dowd GJ; Partin AW; Veltri RW
    Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
    Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
    Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.